Core Viewpoint - The collaboration between Guangxi Shuangyi Pharmaceutical Co., Ltd. and Hubei Jinying Agricultural Development Co., Ltd. aims to enhance the quality and stability of the core raw material, wild chrysanthemum, for Shuangyi's flagship product, Shuangyi Compound Cold Medicine Granules, through standardized planting techniques and a comprehensive supply chain [1][9]. Group 1: Company Collaboration - The visit by Shuangyi's chairman and vice president to Hubei Jinying was focused on exploring the entire supply chain of wild chrysanthemum, including breeding, large-scale cultivation, and processing [1][3]. - Hubei Jinying has established a complete industrial chain for traditional Chinese medicine, with 2,580 acres of medicinal herb cultivation, including 1,030 acres dedicated to wild chrysanthemum [6]. - Shuangyi Pharmaceutical recognizes the advantages of Hubei Jinying's breeding and cultivation techniques, expressing a strong intention to introduce these methods to enhance its own herbal medicine cultivation base [9][11]. Group 2: Product Quality and Market Demand - Wild chrysanthemum is a key ingredient for Shuangyi's products, which include various cold and cough remedies, indicating a significant market demand for this raw material [8]. - The use of Hubei's wild chrysanthemum not only improves the efficacy of Shuangyi's products but also strengthens its competitive edge in the market [9]. - Shuangyi emphasizes its commitment to using authentic medicinal materials, which is crucial for maintaining product quality, especially in light of the recent increase in influenza cases [13]. Group 3: Future Cooperation and Development - The visit established a communication bridge for future collaboration, with both companies aiming to explore new cooperation models that promote resource sharing and complementary advantages [15]. - The partnership is expected to contribute to the high-quality development of the traditional Chinese medicine industry and support rural revitalization efforts [15].

Core Insights - The article highlights a significant increase in respiratory diseases, particularly COVID-19, during the transition from spring to summer, with a notable rise in positive testing rates across various regions in China [1][3]. Group 1: Respiratory Disease Trends - The positivity rate for COVID-19 testing has been on the rise since April, with southern provinces showing a notably higher rate compared to northern ones. The proportion of COVID-19 cases among outpatient flu-like cases increased from 7.5% to 16.2% [1]. - Among adults aged 15 and older, COVID-19 positivity rates are the highest in both outpatient and inpatient cases. The rate of COVID-19 in severe acute respiratory infection cases rose from 3.3% to 6.3% [1]. Group 2: Causes and Transmission - Respiratory infectious diseases are caused by pathogens entering through the respiratory tract, with common pathogens including viruses and bacteria. The fluctuation in temperature and increased humidity in May contribute to a higher survival rate of viruses [3][4]. - The transmission of respiratory diseases occurs through various means, including droplet transmission, airborne transmission, and contact transmission [5][6][7]. Group 3: Prevention Measures - Emphasis is placed on personal hygiene, such as frequent handwashing, especially after contact with public facilities, to reduce the risk of virus transmission [8][9]. - It is recommended to ensure proper indoor air circulation by ventilating spaces at least three times a day for a minimum of 15 minutes to lower indoor virus concentrations [10]. - The article discusses the use of traditional Chinese medicine, specifically the Xia Sang Ju granules, which have shown potential in inhibiting flu and coronavirus, supported by multiple patents for their effective components [12][18].